135 related articles for article (PubMed ID: 29870883)
1. Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines.
Moszczyński-Pętkowski R; Majer J; Borkowska M; Bojarski Ł; Janowska S; Matłoka M; Stefaniak F; Smuga D; Bazydło K; Dubiel K; Wieczorek M
Eur J Med Chem; 2018 Jul; 155():96-116. PubMed ID: 29870883
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
3. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
[TBL] [Abstract][Full Text] [Related]
4. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y; Tanaka Y; Matsumura T; Kadoh Y; Miyoshi H; Hongu M; Takedomi K; Kotera J; Sasaki T; Taniguchi H; Watanabe Y; Takakuwa M; Kojima K; Baba N; Nakamura I; Kawanishi E
Bioorg Med Chem; 2019 Aug; 27(15):3440-3450. PubMed ID: 31235264
[TBL] [Abstract][Full Text] [Related]
6. Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes.
DeNinno MP; Wright SW; Etienne JB; Olson TV; Rocke BN; Corbett JW; Kung DW; DiRico KJ; Andrews KM; Millham ML; Parker JC; Esler W; van Volkenburg M; Boyer DD; Houseknecht KL; Doran SD
Bioorg Med Chem Lett; 2012 Sep; 22(17):5721-6. PubMed ID: 22858141
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.
Chakraborti AK; Gopalakrishnan B; Sobhia ME; Malde A
Bioorg Med Chem Lett; 2003 Apr; 13(8):1403-8. PubMed ID: 12668000
[TBL] [Abstract][Full Text] [Related]
8. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
[TBL] [Abstract][Full Text] [Related]
9. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
[TBL] [Abstract][Full Text] [Related]
10. Adenosine cyclic 3',5',-monophosphate phosphodiesterasr inhibitors. 2.3-Substituted 5,7-dialkylpyrazolo [1,5-a]pyrimidines.
Novinson T; Miller JP; Scholten M; Robins RK; Simon LN; O'Brien DE; Meyer RB
J Med Chem; 1975 May; 18(5):460-4. PubMed ID: 168380
[TBL] [Abstract][Full Text] [Related]
11. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.
Tollefson MB; Acker BA; Jacobsen EJ; Hughes RO; Walker JK; Fox DN; Palmer MJ; Freeman SK; Yu Y; Bond BR
Bioorg Med Chem Lett; 2010 May; 20(10):3120-4. PubMed ID: 20443228
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors.
Dore A; Asproni B; Scampuddu A; Pinna GA; Christoffersen CT; Langgård M; Kehler J
Eur J Med Chem; 2014 Sep; 84():181-93. PubMed ID: 25016376
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase--basic and potential clinical applications.
Hidaka H; Endo T
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():245-59. PubMed ID: 6144253
[No Abstract] [Full Text] [Related]
16. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD
J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
19. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X
Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537
[TBL] [Abstract][Full Text] [Related]
20. Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung.
Fertel R; Weiss B
Mol Pharmacol; 1976 Jul; 12(4):678-87. PubMed ID: 183099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
